Document is current
Any future updates will be listed below
-
Authors
Goswami, Sangeeta https://orcid.org/0000-0001-9201-4503
Gao, Jianjun https://orcid.org/0000-0001-6138-4472
Basu, Sreyashi https://orcid.org/0000-0002-5028-3833
Shapiro, Daniel D.
Karam, Jose A. https://orcid.org/0000-0001-7697-9591
Tidwell, Rebecca Slack https://orcid.org/0000-0003-3041-8582
Ahrar, Kamran
Campbell, Matthew T. https://orcid.org/0000-0003-1915-4491
Shen, Yu
Trevino, Alexandro E. https://orcid.org/0000-0002-9763-1540
Mayer, Aaron T. https://orcid.org/0000-0001-6429-0420
Espejo, Alexsandra B. https://orcid.org/0000-0002-8841-7219
Seua, Christian
Macaluso, Marc D.
Chen, Yulong
Liu, Wenbin
He, Zhong
Yadav, Shalini S.
Wang, Ying
Rao, Priya
Zhao, Li
Zhang, Jianhua https://orcid.org/0000-0001-5412-9860
Jindal, Sonali https://orcid.org/0000-0002-3911-6815
Tannir, Nizar M.
Futreal, Andrew https://orcid.org/0000-0001-8663-2671
Wang, Linghua https://orcid.org/0000-0001-9380-0266
Sharma, Padmanee https://orcid.org/0000-0003-4658-055X
- License Information
-
More Information
Article History
Received: 9 November 2024
Accepted: 3 February 2025
First Online: 21 February 2025
Competing interests
: Dr. Padmanee Sharma’s COI disclosures are as follows as a SAB member for these companies and is not related to any of the work in this paper: Achelois, Adaptive Biotechnologies, Affini-T Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, BioNTech, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Glympse, Henlius/Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, JSL Health, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Matrisome, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Soley Therpeutics, Sporos, Spotlight, Time Bioventures, Trained Therapeutix Discovery, Two Bear Capital, Xilis, Inc. The remaining authors declare no competing interests.
